EUVIMEDEUVIMED entdecken
Scoping ReviewOpen Access · CC BY-NC-ND 4.0

Methodology of analysis of cognitive impairment in longitudinal randomized clinical trials in oncology: a scoping review

François Christy, Florence Joly, Marie Lange, Mylène Duivon, Justine Lequesne

Supportive Care in Cancer · 2026-09 · 34 (9)

DOI: 10.1007/s00520-026-11059-1 ↗

Kurz gefasst

Scoping Review in der Zeitschrift Supportive Care in Cancer, online erschienen am 28.08.2026. Verfasst von François Christy und 4 weiteren Autor:innen. Beteiligte Einrichtung: ANTICIPE U1086 INSERM-UCN, Equipe Labellisée Ligue Contre Le Cancer, Centre François Baclesse, Normandie Université UNICAEN, 14000, Caen, France. f.c…. Hauptthemen laut MEDLINE: Randomized Controlled Trials as Topic, Neoplasms, Cognitive Dysfunction, Chemotherapy-Related Cognitive Impairment. Die Arbeit nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Cancer-related cognitive impairment (CRCI) is a common consequence of cancer treatments. Longitudinal randomized controlled trials (RCTs) are essential to evaluate cognitive outcomes over time, but methodological heterogeneity limits comparability. Accordingly, we systematically review cognition assessment in longitudinal oncology RCTs, focusing on study design, statistical methods, cognitive measures, and adherence to reporting guidelines. METHODS: We reviewed longitudinal RCTs published between 2010-2026 assessing cognition in adult cancer patients. Extracted data included sample size, assessment tools, statistical methods. Methodological quality of reporting was assessed using a subset of the CONSORT 2025 checklist. RESULTS: One-hundred and thirteen studies were included. Trials involved 21% central nervous system (CNS) tumours and 50% of trials focused on breast cancer. Overall, 73% assessed the effects of interventions on cognition, and 27% the impact of cancer or its treatments. Cognition was a primary endpoint in 66% of trials. Objective measures predominated, but International Cognition and Cancer Task Force-recommended tests were underused, and heterogeneity in scoring was observed. The overall RCT median sample size was 81 participants (range: 8-867). Statistical methods varied and were not mutually exclusive: 11% used descriptive analyses only; 24% baseline-adjusted/paired regression; 57% repeated measures; 11% other models. Adherence to reporting guidelines was limited, particularly for missing data (26%) and analysis sample (22%). CONCLUSION: Longitudinal cognitive assessments in oncology RCTs displayed heterogeneity in endpoints, tools, and statistical methods. Small sample sizes limit robustness of results. Future trials should prioritize primary cognitive objective, ensure adequate sample sizes, employ standardized cognitive assessments and appropriate statistical methods to enhance reproducibility and interpretability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Randomized Controlled Trials as TopicNeoplasmsCognitive DysfunctionChemotherapy-Related Cognitive ImpairmentHumansLongitudinal StudiesResearch Design

Stichwörter der Autor:innen

Chemotherapy-related cognitive impairmentCognitionGuidelinesLongitudinal studiesOncologyRandomized controlled trial

Autor:innen und Institutionen

  • ANTICIPE U1086 INSERM-UCN, Equipe Labellisée Ligue Contre Le Cancer, Centre François Baclesse, Normandie Université UNICAEN, 14000, Caen, France. f.christy@baclesse.unicancer.fr.
  • Clinical Research Department, UNICANCER, Centre François Baclesse, 14000, Caen, France. f.christy@baclesse.unicancer.fr.
  • ANTICIPE U1086 INSERM-UCN, Equipe Labellisée Ligue Contre Le Cancer, Centre François Baclesse, Normandie Université UNICAEN, 14000, Caen, France.
  • Services Unit PLATON, Cancer and Cognition Platform, University of Caen Normandy, Caen, France.
  • Clinical Research Department, UNICANCER, Centre François Baclesse, 14000, Caen, France.
  • Medical Oncology Department, Centre François Baclesse Caen, Caen, France.

Zitieren

APA

Christy, F., Joly, F., Lange, M., Duivon, M., & Lequesne, J. (2026). Methodology of analysis of cognitive impairment in longitudinal randomized clinical trials in oncology: a scoping review. Supportive Care in Cancer, 34(9). https://doi.org/10.1007/s00520-026-11059-1

Vancouver

Christy F, Joly F, Lange M, Duivon M, Lequesne J. Methodology of analysis of cognitive impairment in longitudinal randomized clinical trials in oncology: a scoping review. Supportive Care in Cancer. 2026;34(9). doi:10.1007/s00520-026-11059-1

BibTeX
@article{Christy2026,
  author = {Christy, François and Joly, Florence and Lange, Marie and Duivon, Mylène and Lequesne, Justine},
  title = {Methodology of analysis of cognitive impairment in longitudinal randomized clinical trials in oncology: a scoping review},
  journal = {Supportive Care in Cancer},
  year = {2026},
  volume = {34},
  number = {9},
  doi = {10.1007/s00520-026-11059-1}
}
Kostenlos starten →